Not Signed In -
Skin Care |
|
|
Clinical Trial: Neuroskin Forte for Dry Skin Relief in Eczema and Psoriasis
This study is not yet open for patient recruitment.
Verified by University of Medicine and Dentistry New Jersey August 2005
|
Purpose
Patients with dry skin caused by psoriasis or eczema will apply drug or placebo sprays to randomly assigned sides of the body 3 times a day for 8 weeks. The study involves a 10 week commitment with assessments every other week.
| Condition | Intervention | Phase |
|---|---|---|
| Dry skin in psoriasis and eczema | Drug: Drug and Placebo Application | Phase II |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
Official Title: Double-Blind, Bilateral, Vehicle-Controlled, Randomized Trial of Neuroskin Forte to Relieve Symptoms of Dry Skin
Further Study Details:
Primary Outcomes: · Percent improvement from baseline in the Visual Analog Scale (VAS) score for pruritus (itching) at 8 weeks
Secondary Outcomes: · Psoriasis ½-body PGA improvement of at least 2 levels at 8 weeks; · Eczema ½-body IGA improvement of at least 2 levels at 8 weeks; · Improvement in target lesion scoring; · Photography of target lesions
Expected Total Enrollment: 40
Secondary Outcomes: · Psoriasis ½-body PGA improvement of at least 2 levels at 8 weeks; · Eczema ½-body IGA improvement of at least 2 levels at 8 weeks; · Improvement in target lesion scoring; · Photography of target lesions
Expected Total Enrollment: 40
Study start: September 2005; Expected completion: December 2007
Subjects will apply study drug and placebo sprays 3 times a day to the assigned, randomized sides of the body. They are allowed to continue using prescription medications, but not moisturizers. Assessments will be performed every other week. Total duration of the study is 10 weeks (8 weeks of treatment and a follow-up visit 2 weeks later).
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria
· Must be at least 18 years of age and have psoriasis or eczema on both sides of the body, with a pair of roughly symmetrical bilateral "target" lesions at least 1.5 cm in diameter
Exclusion Criteria
- Inability to understand the consent form and/or comply with the requirements of this study
- Use of moisturizers/emollients within 2 days of beginning study
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00143819
Nancy Olesinski 732-418-8470 olesinni@umdnj.edu
New Jersey
UMDNJ Clinical Research Center, New Brunswick, New Jersey, 08903, United States
Nancy Olesinski 732-418-8470 olesinni@umdnj.edu
Study chairs or principal investigators
Alice Gottlieb, MD, PhD, Principal Investigator, University of Medicine and Dentistry New Jersey
More Information
Study ID Numbers: 5494
Last Updated: September 1, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00143819
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-06
Last Updated: September 1, 2005
Record first received: August 31, 2005
ClinicalTrials.gov Identifier: NCT00143819
Health Authority: United States: Institutional Review Board
ClinicalTrials.gov processed this record on 2005-09-06
Resources
- Abnormal Pigmentation (Cleveland Clinic)
- Advanced Techniques For Total Skin Care (Cleveland Clinic)
email this page
print this page
bookmark this page
feedback on this page
